Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This study developed and validated a gradient reversed-phase liquid chromatographic method to effectively measure Finasteride and its related impurities in pharmaceutical bulk drugs, demonstrating high linearity and precision.

This study validated an HPLC analytical method for evaluating fenasteride in commercial products, finding it to be sensitive, selective, and within acceptance criteria for specificity, precision, and stability, making it suitable for quality control testing.

This study developed and validated a sensitive HPLC–MS/MS method for detecting seven prohibited substances in cosmetic products.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.

This study discusses the role of physicians and pharmaceutical companies as entrepreneurial actors in off-label drug use, arguing they may advance patient care more quickly than regulatory agencies.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This study discusses the prevalence and ethical considerations of off-label drug use in dermatology, emphasizing differing perspectives on informed consent between patients and physicians.

This document discusses website navigation and access options for JAMA without presenting any new research findings.

This study developed a new HPLC method for detecting prohibited substances like minoxidil and hydrocortisone in cosmetic products, achieving high sensitivity and successful application to real-world samples.

This article discusses the author's experience with prescribing generic finasteride for hair restoration but reports no new clinical findings.

This study utilized the USFDA AERS to identify significant associations between various medications—such as anti-osteoporotic drugs and phenytoin—and gingival disorders, noting emergent signals with finasteride, COVID-19 vaccine, and levothyroxine, suggesting a need for awareness of oral side effects.

This article provides contact details and affiliations for Amy M. Karch and Fred E. Karch; it presents no new research findings.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

This study developed and validated a precise RP-HPLC-PDA method for estimating finasteride in bulk and tablet forms, suitable for quality control use.

This review discusses various drugs and their uses across multiple therapeutic categories but reports no new clinical results.

This article reviews the historical development of pharmacology up to the mid-20th century and outlines its transition from a support role in therapeutics to a distinct scientific discipline, but reports no new findings.

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.

This study reported that a newly developed UHPLC-MS/MS method detected illegal synthetic hair-growth compounds in 10% of 76 hair-growth products, highlighting the need for ongoing monitoring to protect public health.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.